- Home
- UNCY vs BDTX Comparison
UNCY vs BDTX Comparison
Compare UNCY & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | BDTX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.6M | 104.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UNCY | BDTX |
|---|---|---|
| Price | $3.50 | $1.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $28.40 | $10.00 |
| AVG Volume (30 Days) | ★ 1.0M | 894.1K |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10,044.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $1.60 |
| 52 Week High | $8.74 | $4.94 |
Technical Indicators
Market Signals| Indicator | UNCY | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 46.43 |
| Support Level | $3.35 | $1.61 |
| Resistance Level | $4.18 | $1.93 |
| Average True Range (ATR) | 0.26 | 0.14 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 19.42 | 32.35 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.